Analyse Seer, Inc. (SEER) — Kairos Score 59/100

À propos de Seer, Inc.

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 0 achats et 1 ventes déclarés par les dirigeants de Seer, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur SEER dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur SEER.

• Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
• Seer Announces CFO Transition

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.